TCGA-AR-A1AW-01A-21R-A12P-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 88
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.640
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.440
- COMPLEMENT+0.350
- IL2_STAT5_SIGNALING+0.280
- G2M_CHECKPOINT+0.240
- MITOTIC_SPINDLE+0.240
- KRAS_SIGNALING_UP+0.190
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- NOTCH_SIGNALING-0.410
- GLYCOLYSIS-0.400
- TGF_BETA_SIGNALING-0.380
- ADIPOGENESIS-0.350
- ESTROGEN_RESPONSE_EARLY-0.330
- ESTROGEN_RESPONSE_LATE-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- ANGIOGENESIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.901 |
| 2 | C3N-02922 | — | cohortMD2 | 0.891 |
| 3 | SRR8613787 | — | D | 0.867 |
| 4 | SRR10842377 | — | — | 0.863 |
| 5 | BSR_11_0107_E3_S77 | — | D | 0.861 |
| 6 | SRR8613734 | — | D | 0.859 |
| 7 | BSR_02_0049_A5_S69 | — | D | 0.856 |
| 8 | SRR25043622 | — | — | 0.852 |
| 9 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.850 |
| 10 | SRR8518190 | — | D | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.640 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |